ACE Inhibitor Is Suggested for Heart Disease

NOVEMBER 01, 2003

    Patients with coronary disease should be considered for treatment with an angiotensin-converting enzyme (ACE) inhibitor, said researchers at the August 2003 annual meeting of the European Society of Cardiology. Coauthor of the study Kim Fox, MD, of the Royal Brompton Hospital in London, said that the results of the study showed the clear benefits of adding an ACE inhibitor to the current course of therapy.

    A 4-year study involving >12,000 participants found that patients given the ACE inhibitor perindopril, in addition to standard treatment, had a 20% lower risk of cardiovascular death, heart attack, and cardiac arrest. Dr. Fox called the results a ?milestone in cardiology,? proving for the first time the lifesaving benefits of an ACE inhibitor in a wide range of patients.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.